The latest discoveries in Oncology
Endocrinology
A concise briefing on the most relevant research developments in your field, curated for clarity and impact.
Starving a tumour of fat: a nanogel that boosts checkpoint therapy
This Molecular Pharmaceutics ASAP report describes a thermosensitive berberine-loaded nanogel designed to target CD36, a lipid-uptake pathway that some tumours exploit to fuel growth and resist immune attack. In preclinical triple-negative breast cancer models, the approach is presented as blocking tumour “lipid hijacking” and enhancing responses when combined with anti–PD-L1 immunotherapy, positioning metabolic interference as a potential lever to improve checkpoint efficacy.
Why it might matter to you:
If your work touches immuno-oncology or drug development, this is a concrete example of pairing a tumour-metabolism target with PD-(L)1 blockade to try to widen or deepen responses in a hard-to-treat subtype. It also highlights CD36 as a potentially actionable node for combination strategies and for thinking about biomarkers tied to lipid handling in the tumour microenvironment.
As we continue to impprove, your feedback means a lot to us.
Stay curious. Stay informed — with
Science Briefing.
